Salix Pharmaceuticals, the gastroenterology division of Bausch Health, has launched a new consumer education campaign titled ‘I Wish I Knew’ to raise awareness about Xifaxan® (rifaximin), the only FDA-approved medication for reducing the recurrence risk of overt hepatic encephalopathy in adults with cirrhosis.

The ‘I Wish I Knew’ initiative centers on authentic patient narratives, including a 60-second advertisement featuring a woman reflecting on her experience with overt hepatic encephalopathy symptoms like disorientation and cognitive changes, while emphasizing how treatment helped manage her condition.

The consumer education campaign represents Salix’s continued commitment to patient advocacy. The PSA builds on existing collaborations with organizations like the Global Liver Institute and the American Liver Foundation through additional patient testimonials about living with overt hepatic encephalopathy.

Image Credit: Salix Pharmaceuticals, Bausch Health